Comparative Pharmacology
Head-to-head clinical analysis: RANICLOR versus TRITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RANICLOR versus TRITEC.
RANICLOR vs TRITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist/Antimicrobial Combination